Notably, the administration of a tumor-targeting TLR9 agonist, PIP-CpG, induced a systemic T cell-mediated immune response, promoting the regression of existing mammary tumors and eliciting an immune memory response that delayed the growth of new tumors [34]. Here, TLR9 is linked to neoplasm.